Delivering value-based care is expected to become even more prevalent, driven by factors such as patient comfort with digital tools and advancements in contractual arrangements.
Beth Houck
Advertisement
CEO of SonarMD
Articles by Beth Houck
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Eli Lilly and Novo Nordisk Shift Patients From Compounded Drugs to Lower-Cost Weight-Loss Pills: Report
2
Eli Lilly Enters $202 Million Agreement to Acquire Engage Bio
3
The Evolving Relationship Between FDA and Biotech
4
FDA Approves Datroway for Patients with Metastatic Triple-Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates
5